
    
      This is a multicentre clinical study conducted in Belgium and in The Netherlands. The study
      is a phase I divided in 2 steps: The first step is a dose escalation to define the RD. At the
      second step the PK profile of oral CP-4126 will be compared with the PK profile of IV
      gemcitabine. In addition, the study is conducted to characterize the tolerability of oral
      CP-4126, to evaluate its bioavailability, and to make a preliminary assessment of antitumor
      activity in patients with solid tumours.
    
  